Neuropeptide Y (NPY) is widely expressed throughout the nervous system and is known to reduce excitatory (but also inhibitory) synaptic transmission in many CNS areas, leading to the proposal that it is an endogenous antiepileptic agent. In the neocortex, where NPY is present in ␥-aminobutyric acid (GABA)ergic interneurons, its effects on inhibitory and excitatory synaptic activities have not been completely explored. Here we report that NPY application elicits a long-lasting decrease in evoked excitatory postsynaptic current amplitude and a delayed, long-lasting increase in the amplitude of evoked monosynaptic inhibitory postsynaptic current (IPSC) in layer V pyramidal neurons of rat neocortex. The novel, late, NPY-mediated increase of inhibitory synaptic transmission is caused by modulation of Ca 2؉ -dependent GABA release onto pyramidal neurons, as it was accompanied by an increase in Ca 2؉ -dependent miniature IPSC frequency. NPY decreased evoked monosynaptic IPSCs in GABAergic interneurons, indicating that this neuropeptide has differential effects on different neuronal subtypes in the neocortex. Each of these NPY actions would decrease excitability in cortical circuits, a result that has important implications for both physiological neocortical operations as well as pathophysiological epileptiform activities.
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T he 36-aa neuropeptide Y (NPY) is one of the most abundantly expressed and widely distributed neuropeptides in the central and peripheral nervous system. NPY exerts various biological actions, such as modulation of anxiety, feeding behavior, memory consolidation, and blood pressure regulation (1, 2) . All these effects are mediated by its interaction with Yreceptors, which belong to the G protein-coupled receptor superfamily (3, 4) . In the neocortex and hippocampus, NPY is expressed in ␥-aminobutyric acid (GABA)ergic interneurons (5-7), although, like many other peptides, its synthesis, storage, and release properties are different from those of ''classical'' neurotransmitters. Most recently, results of several studies have indicated that NPY modulates neuronal excitability in many areas of the CNS, and have emphasized its potential role as an endogenous antiepileptic agent (8) . Indeed, it has been found that NPY expression increases in those brain areas undergoing seizure activity (9) (10) (11) (12) , that NPY receptor binding properties and expression are altered by seizures in various animal models of epilepsy (13, 14) , and that NPY-deficient mice are more susceptible to seizure-induced death (15) . Moreover, exogenous NPY application can decrease the frequency of cortical and hippocampal epileptiform discharges (16) (17) (18) (19) . The mechanism underlying the NPY-mediated reduction of epileptiform discharges is attributed to a G protein-dependent decrease in calcium channel functionality leading to a reduced release of glutamate from presynaptic terminals, as has been reported in the hippocampus (20) (21) (22) . In line with this result, NPY has been found to reduce presynaptic release of glutamate (23) and GABA (24, 25) from neurons in different brain areas.
Because it is stored in large dense core granules, NPY is likely released during sustained high-frequency activity (5-40 Hz; ref. 26) , such as that occurring during epileptiform seizures. Although NPY expression is well documented in the neocortex, little is known about its modulatory effects on synaptic transmission, and in particular on GABAergic inhibition, in neocortical neurons. Here we report that exogenously applied NPY reduces glutamatergic neurotransmission onto layer V pyramidal neocortical neurons, as is the case in hippocampal pyramidal cells (21, 22) . Additionally, however, exogenously applied NPY has two previously undescribed effects: a long-lasting increase in Ca 2ϩ -dependent inhibitory synaptic transmission onto neocortical pyramidal neurons, as well as prolonged decreases in the amplitude of evoked monosynaptic inhibitory postsynaptic currents (IPSCs) in interneurons. Taken together, these differential actions would contribute to powerful anticonvulsant effects of NPY in neocortex.
Methods
In Vitro Slice Preparation and Electrophysiology. Techniques for preparing neocortical slices and recording from visualized neurons were essentially as described (27, 28) . P13-P21 SpragueDawley rats were killed with pentobarbital (50 mg͞kg); brains rapidly removed and immersed in ''cutting'' solution containing (in mM) 234 sucrose, 11 glucose, 24 NaHCO 3 , 2. 29 ] was fastened to the stage of a vibratome with cyanoacrylate glue, submerged in the cutting solution, and 300-m-thick coronal slices were cut. Slices were then incubated in oxygenated artificial cerebrospinal fluid (ACSF) containing (in mM) 126 NaCl, 26 NaHCO 3 , 2.5 KCl, 1.25 NaH 2 PO 4 , 2 MgSO 4 , 2 CaCl 2 , and 10 glucose, pH 7.4, initially at 32°C for 1 h, and subsequently at room temperature, before being transferred to the recording chamber. Recordings were obtained at 32°C from layer V pyramidal neurons and interneurons in the sensorimotor cortex. Neurons were visually identified with infrared video microscopy. Firing behavior in current-clamp and the presence or absence of a large emerging apical dendrite were used to distinguish between pyramidal neurons and interneurons, respectively (e.g., Figs. 1A and 4A). These selection criteria have been validated in other experiments in our laboratory that used intracellular biocytin labeling (30, 31) . For experiments on IPSCs, patchclamp electrodes (tip resistance ϭ 2-5 M⍀) were filled with an intracellular solution containing (in mM) K gluconate 70, KCl 70, NaCl 2, Hepes 10, EGTA 4, MgATP 4, and Na 2 GTP 0.3, pH 7.3, corrected with KOH; 290 milliosmolal. The estimated E Cl was ϷϪ16 mV based on the Nernst equation, with no correction for liquid junction potentials. Under these recording conditions, activation of GABA A receptors resulted in inward currents at a holding potential (V h ) of Ϫ70 mV. Series resistance was continuously monitored during each recording, and data from cells showing changes Ͼ15% of the initial value were rejected.
␣-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor-mediated excitatory postsynaptic currents (EPSCs) were recorded by using an intracellular solution containing (in mM) 120 cesium gluconate, 1 MgCl 2 , 1 CaCl 2 , 11 KCl, 10 Hepes, 2 NaATP, 0.3 NaGTP, 1 QX-314, and 11 EGTA; pH 7.3 corrected with Cs-OH; 290 milliosmolal. Drugs were delivered by using a local perfusion system (25, 27) composed of multiple fine tubes ending in a common outlet tube, positioned in proximity (ϳ250 M) to the recorded neuron. IPSCs were isolated in 10 M 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX) and 100 M DL-2-amino-5-posphonovaleric acid (DL-APV), both in the bath and local perfusate. Miniature (m)-IPSCs were recorded in the presence of 1 M tetrodotoxin (TTX). AMPA receptor-mediated EPSCs were isolated in 50 M picrotoxin, 50 M D-APV, and 50-75 nM 2,3-dihydroxy-6-nitro-7-sulfamoylbenzo[f]quinoxaline (NBQX), to prevent epileptiform activity (27) . Extracellular stimuli, consisting of constant current pulses 50-130 s in duration and 100-500 A in amplitude, were delivered at low frequencies (0. 
Results

NPY Exerts a Differential Action on IPSCs and EPSCs in Pyramidal
Neurons. To study the effects of NPY on synaptic transmission onto pyramidal neurons, we performed whole-cell recordings from layer V pyramids, visually identified as large cells with an apical dendrite extending toward the pial surface ( Fig. 1 A Left) . These neurons had a characteristic adapting firing behavior during injection of depolarizing current pulses ( Fig. 1 A Right) . Extracellular stimulation in the presence of glutamate receptor blockers 2-amino-5-posphonovaleric acid (APV; 100 M) and 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX; 20 M) evoked in pyramidal cells monosynaptic GABAergic IPSCs that were blocked by 10 M gabazine (data not shown). The effects of a local perfusion of NPY (1 M; 10 min) on these IPSCs were assessed. During NPY application, a slight decrease, increase (Fig. 1B) , or no effect could be detected, but a persistent increase in inhibitory synaptic transmission invariably appeared during NPY washout (Fig. 1D) . The increase in evoked IPSC amplitude persisted as long as the recording remained stable, Ͼ1 h. The frequency of spontaneous IPSCs (sIPSCs) recorded between evoked IPSCs was variable but not significantly affected during or after NPY application compared with control ACSF perfusions, suggesting that neither mIPSC (see below) nor impulserelated IPSC frequency was significantly affected by the peptide. The alterations in evoked IPSCs could not be attributed to changes in the quality of recordings, because series resistance and holding current remained stable in the records selected for analysis (see Methods; n ϭ 8; Fig. 1B ). Focally applied NPY had no effect on membrane conductance at resting membrane potential, as judged by the absence of a shift in holding current. To rule out the possibility that the NPY-dependent long-lasting increase in IPSC amplitude was simply the result of the stimulation protocol or local application methodology, similar experiments were performed in which the extracellular perfusate contained ACSF plus the glutamate receptor blockers but no NPY. No effect on IPSC amplitudes was detected in these ACSF-perfused neurons (n ϭ 7; Fig. 1 C and D) .
To test whether the late NPY effect on IPSCs was due to limited diffusion of the peptide into the slice, we varied the duration of the NPY perfusion, using more prolonged applications (30 min). During the 30-min perfusions, no statistically significant change of evoked IPSC amplitudes was observed in pyramidal neurons (P Ͼ 0.2 at the 30th minute of NPY perfusion, compared with control; paired t test, n ϭ 4; data not shown), but a long-lasting potentiation of evoked IPSC amplitudes appeared during NPY washout (P Ͻ 0.005 after 20 min in washout, compared with control; paired t test, n ϭ 4; data not shown). Thus, the delay to the enhancement of evoked IPSCs was longer with 30-min perfusions than that found with 10-min NPY perfusions when the increase in IPSC amplitudes began within Ϸ10 min after the NPY application (Fig. 1D) . Moreover, preliminary experiments, in which NPY was perfused for just 1 or 2 min, resulted in a long-lasting IPSC potentiation, appearing soon after NPY was washed out (data not shown). These results indicate that the delayed effect of NPY on GABAergic neurotransmission onto pyramidal neurons cannot be related to a slow action of the peptide or delayed penetration into the slice.
This enhancement of GABAergic neurotransmission represents a novel action of NPY, which has commonly been associated with a decrease in synaptic function (21) (22) (23) (24) (25) . We therefore tested the effect of NPY on glutamatergic neurotransmission in neocortical pyramidal neurons to determine whether it would have depressant actions similar to those reported in hippocampal pyramidal neurons (21, 22) . AMPA-mediated EPSCs were isolated in the presence of the GABA A receptor blocker picrotoxin (50 M) , the N-methyl-D-aspartate receptor blocker APV (50 M), and low concentrations of the AMPA receptor blocker 2,3-dihydroxy-6-nitro-7-sulfamoylbenzo[f]quinoxaline (NBQX; 50-75 nM) to prevent epileptiform activity (27) . As expected, NPY application elicited a decrease in amplitudes of evoked EPSCs in pyramidal cells. This alteration in evoked EPSCs was persistent for many minutes after cessation of NPY application, but, unlike the effect on evoked IPSCs, depression of EPSCs usually began during NPY perfusion (n ϭ 9; compare Fig. 1 D  and E) . Control perfusion of ACSF did not change glutamatergic neurotransmission (n ϭ 7; Fig. 1E ). These data are consistent with a reported action of NPY on glutamatergic neurotransmission in cortical structures (21, 22) . Thus, NPY has differential actions on GABAergic and glutamatergic neurotransmission in neocortical pyramidal neurons, with the former being augmented and the latter decreased. mitter release has been shown to occur only through Ca 2ϩ -dependent mechanisms in the hippocampus (21) and in the thalamus (25) . We therefore tested the possibility that the effect of NPY on the amplitude of evoked action potential-dependent IPSCs was due to enhanced Ca 2ϩ -dependent release of GABA onto pyramidal neurons. Application of elevated [K ϩ ] o presumably generates a steady-state depolarization of presynaptic terminals, resulting in persistent influx of calcium, making it possible to analyze the effects of NPY on Ca 2ϩ -dependent synaptic transmission. mIPSC frequency, but not amplitude, was strongly increased when [K ϩ ] o was raised from 2.5 to 20 mM (Fig.  3 A and B) , consistent with an increase in Ca 2ϩ -dependent release (32) . During NPY application under these conditions, there was a slight but statistically insignificant decrease of mIPSC frequency (95 Ϯ 8% of control; n ϭ 6, P Ͼ 0.05; Fig.  3C1 ). However, later during NPY washout, mIPSC frequency was significantly increased (130 Ϯ 8% of control; n ϭ 6, P Ͻ 0.05; Fig. 3A 10-min washout and Fig. 3 B and C1 ), an effect that was similar in its delayed onset to the increase in evoked IPSC amplitudes after NPY perfusion (e.g., Fig. 1 B and D) . Addition of the Ca 2ϩ channel blocker Cd (Fig. 3 B and C2) . (Fig. 3C2 , NPY͞vehicle and washout, 10 min). In these control experiments, no significant effects on mIPSC frequency or amplitude were detected over the same time course in which the NPY-induced effect on mIPSC frequency was evident. These data indicate that NPY application results in an increased Ca 2ϩ -dependent release at GABAergic terminals contacting pyramidal neurons.
NPY Reduces Evoked IPSCs in Neocortical Interneurons.
To determine whether inhibitory neurotransmission onto inhibitory interneurons might be similarly affected by NPY, we performed wholecell recordings from layer V interneurons, which were visually identified as round multipolar cells lacking an apical dendrite (Fig. 4A) . On the basis of their firing behavior after injection of current pulses, GABAergic interneurons fell into two groups: the fast-spiking (FS) and low-threshold-spiking (LTS) cells (7, (33) (34) (35) (36) . In contrast to the effects seen with pyramidal neurons, NPY elicited a robust and long-lasting decrease in the amplitude of evoked monosynaptic IPSCs in six FS and three LTS cells that were tested (Fig. 4 B and C; see Methods and Fig. 1 ). Significant changes in monosynaptic IPSC amplitudes did not occur in control experiments in which control ACSF was perfused instead of NPY (Fig. 4C, ACSF ; total number of interneurons ϭ 5), indicating that the long-lasting depression of IPSCs was mediated by neuropeptide Y, rather than a nonspecific effect of the perfusion or the stimulation pattern.
Discussion
These experiments provide evidence for significant effects of exogenously applied NPY on both excitatory and inhibitory synaptic transmission onto layer V neocortical neurons and on inhibition of interneurons. Consistent with the reported reduction of EPSCs in hippocampal pyramidal neurons (21, 22) , NPY decreased AMPA receptor-mediated glutamatergic neurotransmission onto neocortical pyramidal neurons. Although results in hippocampus have indicated that NPY does not affect GABAergic neurotransmission onto pyramidal neurons (37) , this neuropeptide can modulate GABAergic synaptic transmis- sion in other brain areas (24, 25, 38) . Here we report an action of NPY in the neocortex, namely induction of a long-lasting increase of GABAergic neurotransmission on neocortical pyramidal neurons. This effect on evoked IPSCs might be attributed to an increase in action potential-dependent neurotransmitter release from presynaptic terminals, an enhanced postsynaptic GABA A -receptor sensitivity, or both effects. A postsynaptic effect seems unlikely, because the amplitude of mIPSCs was unchanged by NPY perfusion in either normal ACSF or in- Fig. 2 B and C; Fig. 3 B and C2) . We did not detect an NPY-mediated alteration in the frequency of mIPSCs recorded in pyramidal neurons in normal [K ϩ ] o . This finding is consistent with reports that NPY does not affect Ca ] o , NPY application increased mIPSC frequency with no effect on mIPSC amplitude, indicating that the peptide enhances Ca 2ϩ -dependent release of GABA from interneuronal presynaptic terminals. An alternative (or perhaps additional) mechanism for the NPY-mediated potentiation of inhibition on pyramidal neurons might derive from an increased excitability (e.g., depolarization) of interneurons by the neuropeptide, causing increased numbers of interneurons to discharge after the extracellular stimulus. The absence of increased sIPSC frequency in pyramidal cells would argue against a direct excitatory effect of NPY on interneurons, as would the lack of a shift in holding current when NPY was applied to FS or low-threshold-spiking cells. However, interneuronal membrane properties were not examined in detail in control and NPY-containing solutions to test this possibility directly.
The effect of NPY on both evoked monosynaptic IPSCs and Ca 2ϩ -dependent mIPSCs in pyramidal cells is delayed and long-lasting. During NPY application, individual cells varied in their responses, generating a slight decrease, an increase, or no effect. However, the persistent increase in inhibitory synaptic transmission invariably appeared during NPY washout. Ca 2ϩ -dependent mIPSC frequency showed similar changes during NPY perfusion, but even when a decrease was present during NPY perfusion, a consistent and significant potentiation occurred after the peptide was washed out (see Fig. 3C1 ). The reason for this delayed effect is unclear. The more rapid onset of NPY effects on EPSCs vs. IPSCs (compare Fig. 1 D and E) and the results of prolonged (30-min) applications rule out delayed penetration into the slice as an explanation for delayed onset. Also, in other experiments in our laboratory, the same perfusion system has been used to apply NPY to thalamic slices, resulting in relatively rapid responses and washout (25) . Moreover, preliminary experiments in which NPY was applied for much briefer time periods (1-2 min) resulted in an increase of evoked IPSCs soon after NPY washout (unpublished observation). A shorter response latency is also apparent in studies of NPY effects on evoked glutamatergic neurotransmission in the hippocampus (22) and in the arcuate nucleus (23) . The delayed effect of NPY on IPSCs could be caused either by slow activation of Y receptors or by a ''rebound'' effect after NPY washout. The lack of effect on IPSCs during 30-min perfusions of NPY argues against the former possibility, as do data showing that NPY applied for 1 or 2 min still elicits an increase of evoked IPSCs during washout. The robust increase in evoked IPSCs during NPY washout indicates that the peptide is able to induce a long-term potentiation of inhibition on pyramidal neurons on its removal from the slice.
One admittedly speculative explanation for the long delay in the onset of NPY effects on inhibitory neurotransmission would be a simultaneous activation of two or more Y receptor subtypes, whose effects offset one another, and whose time courses are different. During washout, the depressant effect might be reversed, whereas the potentiating action, likely due to the activation of long-lasting modifications in the presynaptic terminal, would persist.
The NPY-mediated increase in GABAergic neurotransmission recorded in pyramidal neurons is accompanied by a concurrent long-lasting decrease in evoked IPSC amplitudes in both FS and low-threshold-spiking layer V interneurons. One possible explanation for these results would be a target-specific difference in NPYergic modulation of terminals from single interneurons that are presynaptic to pyramidal cells vs. other interneurons (39) . This selectivity of action might be mediated by different receptors and͞or different intracellular coupling mechanisms. An alternative mechanism might involve differen- tial effects of NPY on subsets of ''interneuron-selective'' vs. ''pyramidal neuron-targeting'' GABAergic cells (40, 41) .
NPY-induced disinhibition of interneurons would increase their output and amplify the overall effects of the peptide on Ca 2ϩ -dependent release of GABA from inhibitory terminals on pyramidal neurons (e.g., Fig. 3 ), resulting in a powerful potentiation of their inhibitory responses. Interneuronal activity in the neocortex is important in generating and sustaining network oscillations underlying several brain functions (42) , and inhibition of GABAergic responses on interneurons should have important consequences for the function of their target downstream pyramidal neurons. Polysynaptic IPSCs in layer V pyramidal neurons are significantly larger in amplitude than monosynaptic IPSCs (43) . Therefore, an estimate of the net effects of NPY on inhibition in the cortical network will require further experiments to determine whether excitatory synaptic events onto interneurons are decreased, as they are in pyramidal cells, and whether this would, in part, oppose the facilitatory effects described here.
The mechanisms of action of NPY on excitation and inhibition of pyramidal neurons and on inhibition of interneurons have not been completely investigated. In the hippocampus, the NPYmediated decrease of glutamate release onto pyramidal neurons has been attributed to the activation of Y2 receptors (22) but this might not be the case in neocortex where Y1 is a highly expressed receptor subtype, and Y2 receptors are much less prominent (44) (45) (46) (47) . Indeed, the antiepileptic effects of NPY in hippocampus and cortex seem to be mediated by different Y-receptor subtypes (16, 18) . Moreover, Y5 receptor activation has been implicated in decreasing glutamate release in the hippocampus (48) and in reducing seizures in different rat models of epilepsy (49, 50) . The various NPY-mediated effects on synaptic transmission in neocortical pyramidal neurons and interneurons suggest the involvement of multiple receptors and possibly different intracellular coupling mechanisms. In any case, our results in neocortex show that NPY can affect inhibitory as well as excitatory synaptic events. The combined effects of potentiation of inhibition and the depression of excitation on pyramidal neurons, together with the depression of inhibition on interneurons, and the presumed release of NPY by high-frequency seizure-related neuronal firing, make this peptide a powerful endogenous antiepileptic agent.
